Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Different studies published in the last years have focused on the psychotropic effects of carbamazepine (CBZ). This study tries to investigate the efficacity of CBZ as an adjunct treatment of schizophrenia. 20 patients with a diagnosis of paranoid schizophrenia, according to the RDC, have been investigated by double-blind method. Subjects are divided in two groups (n = 10). The first one is treated with CBZ (with dose in order to reach a plasma level between 8-12 mg /l) and Haloperidol (oral fixed dose: 30 mg /day). The second group only with Haloperidol (same dose). Clinic and psychopathological disturbances are evaluated with the BPRS, and secondary effects with the UKU scale. A clinical improvement (90%, measured by the BPRS) was observed for both groups, without significant differences. Patients treated with CBZ show an important reduction of neurological secondary effects related to neuroleptics (Haloperidol). Carbamazepine appears to be a useful treatment, combined with neuroleptics, for acute schizophrenic episodes.
 ...
PMID:[Carbamazepine: an efficient adjuvant treatment in schizophrenia]. 150 60

A total of 1018 and 812 first degree relatives (FDR) of schizoprencies and controls respectively, were studied to find out the psychiatric morbidity in the families of paranoid and non-paranoid schizophrenia patients. The risk of schizophrenia and affective disorders was found to be independent of the probands subtype diagnosis. The risk for schizoid-schizotypal and paranoid personality disorders was found to be increased in the first degree relatives of paranoid schizophrenic, as compared to non-paranoid schizophrenic, thus suggesting that the psychopathology in the FDR may differ with the subtype diagnosis of the proband.
 ...
PMID:Psychiatric morbidity in the families of paranoid and non-paranoid schizophrenia patients. 159 11

A study was made of the incidence of HLA histocompatibility antigens of A, B and C loci in 100 male patients suffering from paranoid continuous schizophrenia associated with hallucinatory paranoid symptomatology during the formation in them of therapeutic resistance. In accordance with the clinico-pathogenetic philosophy, 2 groups of resistant patients were formed: an "endogenous" one (because of rapid progression) and a "pharmacogenous" one (secondary, formed by the mechanisms of "adaptation" to neuroleptics). In addition, a group of "nonresistant" patients (a reference one) was also distinguished. The data were compared to those obtained in normal subjects (50 men) and to those derived within the distinguished groups, employing mathematic computation of the risk coefficient. It has been shown that in contrast to the group of normal subjects, the general group of patients suffering from paranoid schizophrenia manifested the accumulation of the HLA antigens A2, A9, W7 and B15. The accumulation of the HLA antigens A2 and A11 was characteristic of the patients suffering from "endogenous" resistance, which distinguished those patients from normal subjects, from "nonresistant" patients and those with "pharmacogenous" resistance. The HLA phenotype A2,11 can be regarded as a potential marker of progression (risk grades 9.8). Besides, it has been demonstrated that the HLA antigens B7 may attest to risk of tolerance to psychopharmacotherapy and formation of "pharmacogenous" resistance (risk grades 4.3).
 ...
PMID:[HLA immunogenetic markers in predicting therapeutic resistance in paranoid schizophrenia]. 164 51

The pharmacological treatment for paranoid schizophrenia is based on antipsychotic drugs. Their actions is only suspensive but not curative. In 1980 Crow proposed a division of schizophrenia in two major syndromes, type 1 being characterized by prominent positive symptoms. Andreasen in 1982 suggested similar criteria for positive subtype. Many others have described schizophrenia subtypes over the years. The paranoid schizophrenia criteria are very close to Crow's type 1 criteria. Since chlorpromazine was synthetized in France in 1952, the French speaking psychiatrists have classified neuroleptics according to their therapeutic efficacy and their side effects. So Deniker and Ginestet categorized neuroleptics on the basis of their behavioural efficacy and distinguished sedative neuroleptics from anti-delusional neuroleptics and anti-autistic neuroleptics. French psychiatrists consider that there are qualitative differences between various neuroleptics. In USA, equivalent doses are established with chlorpromazine for many neuroleptic drugs, but equivalency doses are considered as crude at best by some, such as J.M. Kane. The typical neuroleptic treatment is reviewed: target symptoms, choice of drug, dosage, route of administration, combined medications, predictive clinical and biological parameters of response, duration of treatment. Failure to response to neuroleptic treatment is not uncommon. Some strategies are detailed for the treatment-resistant patients. Combination of neuroleptics like haloperidol + thioproperazine or haloperidol + trifluoperazine may be useful.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Principles of chemotherapy of paranoid schizophrenia]. 168 23

Lipid peroxidation (LPO) processes and the status of the ++bio-antioxidant defence system were studied in 133 male patients with continuous paranoid schizophrenia associated with hallucinatory and paranoid symptomatology, refractory to treatment. According to the ++clinico-pathogenetic principle, 3 groups of resistant patients were made up: an "endogenous" one (because of high progression), a "pharmacogenous" one (secondary, formed in accordance with the mechanisms of "adaptation" to neuroleptics, and a "resistant" one formed on the "pathological ground". The data were compared both to the normal patients (control) and to those in patients with acute paranoid schizophrenia and in a state of a remission. All the examined patients showed activation of LPO while the patients with acute schizophrenia were marked by a dramatic increase (by 2.5 to 3 times) of the intensity of LPO as compared to normals. During formation of therapeutic resistance, all the groups, in addition to the high values of the LPO intensity, demonstrated remarkable signs of depletion of the ++bio-antioxidant defence system, particularly in the group with resistance on the "pathological ground".
 ...
PMID:[Significance of disorders of the processes of lipid peroxidation in patients with persistent paranoid schizophrenia resistant to the treatment]. 168 58

To explore the validity of different approaches for subtyping schizophrenia, the conditions of 187 schizophrenic patients from the Chestnut Lodge follow-up study were rediagnosed with the use of classic subtype criteria. Independently collected data allowed construction of a longitudinal profile of the natural history of illness for patients who met operational criteria for paranoid (n = 78), hebephrenic (n = 26), and undifferentiated (n = 83) schizophrenia. Paranoid schizophrenia had an older age at onset, often developed rapidly in individuals with good premorbid functioning, tended to be intermittent during the first 5 years of illness, and was most associated with good outcome or recovery. Hebephrenia had an earlier age at onset, often developed insidiously, and was associated with a greater family history of psychopathology, poor premorbid functioning, and, frequently, a continuous illness with a poor long-term prognosis. While also early and insidious in onset, unlike hebephrenia, undifferentiated schizophrenia was poorly distinguished from the patients' premorbid state, associated with an early history of behavioral difficulties, and often resulted in a continuous but stable disability. We discuss implications for nosology. Although distinctive patterns were discernible, the considerable heterogeneity within subtypes calls for continued efforts to develop and explore alternate classification schemes.
 ...
PMID:Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. 174 20

In subtypes of schizophrenia and unipolar depression, both increased and decreased levels of platelet serotonin were found. Hyperserotonemia was usually observed in patients with psychotic features (i.e., in paranoid schizophrenia and psychotic depression). Hyposerotonemia, although less common than hyperserotonemia, was present in nonparanoid schizophrenia and nonpsychotic depression (i.e., in patients without psychotic symptoms). A sex difference in platelet monoamine oxidase activity was observed among healthy subjects, but not among schizophrenic patients. The activity of platelet monoamine oxidase in paranoid and nonparanoid schizophrenic patients did not differ from that in healthy subjects. The findings in this study suggest that biological differences between subtypes of unipolar depression or schizophrenia might depend upon the presence of psychotic symptoms.
 ...
PMID:Platelet serotonin in subtypes of schizophrenia and unipolar depression. 175 25

In contrast to contemporary approaches to psychopathology that establish diagnostic taxonomies derived primarily from differences in manifest symptoms, this paper, based on an integration of cognitive and psychoanalytic developmental theory, proposes a structural cognitive morphology for understanding and assessing differences among various forms of psychopathology, from schizophrenia to the neuroses. A theoretical model based on the development of cognitive schema, consistent with clinical and research data, considers schizophrenia and paranoid schizophrenia as involving fundamental disturbances in boundary articulation and recognition constancy, and considers borderline personality disorders as involving disturbances in evocative constancy. Also, a lack of integration of object and self-schema, expressed in either a distorted and exaggerated preoccupation with interpersonal relatedness or self-definition, defines two primary personality configurations that have implications for understanding the neuroses and subtypes of depression, as well as differential response to various types of psychotherapeutic intervention.
 ...
PMID:A cognitive morphology of psychopathology. 185 7

Eighteen unmedicated chronic schizophrenic patients and 13 normal controls were tested in a paradigm designed to examine functional changes in electroencephalographic (EEG) activity following presentation of emotionally salient auditory stimuli and control tones. Five standard bands of EEG spectral power were examined at bilateral frontal and temporal surface recording sites. The schizophrenic subjects were assigned to diagnostic subgroups on the basis of DSM-III-R criteria following independent clinical examination by two staff psychiatrists. Those subjects who met DSM-III-R criteria for paranoid schizophrenia were assigned to one subgroup (PS subgroup), while those who met DSM-III-R criteria for either residual or undifferentiated schizophrenia were assigned to a second subgroup (R/US subgroup). Analysis of Variance of EEG activity recorded at bilateral frontal (F1 and F2) and temporal (T3 and T4) scalp leads revealed significant diagnosis-related differences in alpha and beta-2 activity at temporal recording sites, and in beta-1 and beta-2 activity at frontal recording sites. Post-hoc tests revealed that significant differences in all four measures occurred in the R/US subgroup, which showed a decrease in temporal alpha and an increase in temporal beta-2 power as compared to controls. These variations in EEG activity appeared to demonstrate a degree of subgroup specificity, as the R/US subgroup also differed significantly from the PS subgroup on most of these measures. Significant subgroup-specific lateralization effects were also observed for temporal lobe delta activity and for frontal lobe beta-1 activity. These findings are interpreted in terms of subgroup-specific alterations in the processing of sensory information in schizophrenia, particularly when such information is emotionally salient. They suggest that subgroup differences in emotional and clinical state may be reflected in differential changes in EEG spectra within the schizophrenic population.
 ...
PMID:EEG power variation in schizophrenic subgroups: effects of emotionally salient stimuli. 191 24

In a combined twin-family study, the concordance for subtype of schizophrenia was investigated. The sample included 31 monozygotic (MZ) and 28 dizygotic (DZ) twin probands fulfilling the criteria of DSM-III-R schizophrenia. Their co-twins and first-degree relatives were personally interviewed and diagnosed in accordance with DSM-III-R. Any twin or relative diagnosed as schizophrenic was subclassified as either paranoid or nonparanoid. Schizophrenia was more often observed in co-twins of MZ probands with nonparanoid schizophrenia than in MZ probands with paranoid schizophrenia, indicating a stronger genetic influence in nonparanoid schizophrenia. Fifteen MZ pairs were concordant for schizophrenia, and 13 of these pairs were also concordant for subtype. Such a relationship was not observed in the first-degree relatives with schizophrenia. Our results indicate a complex etiology of subtypes in schizophrenia, and to some extent the etiology of subtypes may differ from the etiology of schizophrenia.
 ...
PMID:Subtypes of schizophrenia--evidence from a twin-family study. 195 Jun 18


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>